Nuclear Medicine and & Immunology (1st ed\/1e 2022) First Edition PDF<\/p>\n
CONTENTS<\/p>\n
1 Introduction on Nuclear Medicine and Immunology . . . . . . . . . 1
\nSara Harsini, Abass Alavi, and Nima Rezaei
\n2 Nuclear Imaging of Endogenous Markers of Lymphocyte
\nResponse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
\nIsrat S. Alam, Travis M. Shaffer, and Sanjiv S. Gambhir
\n3 Radioimaging of Activated T Cells in Preclinical
\nand Clinical Cancer Investigations . . . . . . . . . . . . . . . . . . . . . . . . 61
\n\u00c1ron Roxin and Fran\u00e7ois B\u00e9nard
\n4 Gallium Imaging of Infection and Inflammation . . . . . . . . . . . . . 103
\nMariza Vorster and Mike Sathekge
\n5 111Indium-Labeled Leukocyte Imaging of Infection
\nand Inflammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
\nSara K. Meibom, Ilan Y. Benador-Shen,
\nand Gustavo A. Mercier
\n6 [
\n99mTc]Tc-HMPAO-Labeled Leukocyte Imaging of
\nInfection and Inflammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
\nJoanna E. Kusmirek and Scott B. Perlman
\n7 2-[18F]FDG PET Imaging of Infection and Inflammation . . . . . . 179
\nRyogo Minamimoto
\n8 2-[18F]FDG PET\/CT in Fever of Unknown Origin . . . . . . . . . . . . 209
\nIlse J. E. Kouijzer, Chantal P. Bleeker-Rovers,
\nand Lioe-Fee de Geus-Oei
\n9 Tumor-Targeting Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 217
\nDhritiman Chakraborty, Abhijit Das, and C. S. Bal
\n10 Tumor Architecture and Targeted Delivery . . . . . . . . . . . . . . . . . 237
\nDhritiman Chakraborty, Abhijit Das, Meghana Prabhu,
\nKonudula Sreenivasa Reddy, Saurabh Arora, and C. S. Bal
\n11 Radionuclide Therapy and Immunomodulation . . . . . . . . . . . . . 249
\nRachel Anderson and Katherine Vallis<\/p>\n
12 Translational Development and Testing of Theranostics
\nin Combination with Immunotherapies . . . . . . . . . . . . . . . . . . . . 267
\nPeter M. Carlson and Zachary S. Morris
\n13 Radioimmunotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 281
\nMajid Assadi and Ali Gholamrezanezhad
\n14 Radiolabeled Antibodies for Cancer
\nRadioimmunotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 297
\nJulie Rousseau, Joseph Lau, and Fran\u00e7ois B\u00e9nard
\n15 Dosimetric Principles of Targeted Radiotherapy
\nand Radioimmunotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 347
\nGiuseppe De Vincentis, Viviana Frantellizzi,
\nand Massimiliano Pacilio
\n16 Theranostics of Hematologic Disorders . . . . . . . . . . . . . . . . . . . . 359
\nArif Sheikh, Shazia Fatima, Zain Khurshid,
\nand Zaheer Chiragh
\n17 Radioimmunotherapy of Acute Leukemia . . . . . . . . . . . . . . . . . . 433
\nRoland B. Walter and Johnnie Orozco
\n18 Targeted Radionuclide Therapy and Immunotherapy
\nof Metastatic Prostate Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . 449
\nHossein Jadvar
\n19 Radioimmunotherapy and Targeted Radiotherapy
\nof Squamous Cell Carcinoma of the Head and Neck . . . . . . . . . . 457
\nSiroos Mirzaei and Heying Duan
\n20 The Use of PET in Evaluating the Efficacy of
\nImmunotherapy in Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 471
\nJudy Nguyen, Carina Mari Aparici, Sundeep Nayak, and
\nBenjamin L. Franc
\n21 Moving Forward: Expected Opportunities for the
\nDevelopment of New Therapeutic Agents . . . . . . . . . . . . . . . . . . . 495
\nPhilip F. Cohen, Tassia R. M. de Godoy, and Kalevi Kairemo<\/p>\n
This book explores the close connection between immunology and nuclear medicine, which has led to radioimmunoimaging and radioimmunotherapy (RIT).<\/p>\n
Molecular imaging with positron emission tomography (PET) and single-photon emission computed tomography (SPECT) is increasingly being used to diagnose, characterize, and monitor disease activity in the context of inflammatory disorders of known and unknown etiology, such as sarcoidosis, atherosclerosis, vasculitis, inflammatory bowel disease, rheumatoid arthritis, and degenerative joint disease. The first chapters discuss the various radiopharmaceutical agents and radiolabeled preparations that have been employed in inflammation imaging. Of these, FDG-PET imaging has been shown to have the great value in the detection of inflammation and has become the centerpiece of several initiatives over the last several years. This very powerful technique will play an increasingly important role in the management of patients with inflammatory conditions in the future.<\/p>\n
The book also explores the growing role of nuclear medicine and molecular imaging in the diagnosis and treatment of cancer. The rapid pace of change has been fueled by advances in our understanding of tumor biology, on the one hand, and the development of specifically targeted medical therapies, diagnostic agents, and radiotherapies, on the other.<\/p>\n
Written by leading international experts in the field, this book is an invaluable tool for nuclear medicine physicians, radiologists, oncologists, and immunologists.<\/p>\n","protected":false},"excerpt":{"rendered":"
Nuclear Medicine and & Immunology (1st ed\/1e 2022) First Edition PDF by Sara Harsini (Editor), Abass Alavi (Editor), Nima Rezaei (Editor)<\/p>\n